Want to join the conversation?
$AMGN said it received a provisional permission from EU to market BLINCYTO (blinatumomab) which is used for the treatment of Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia. The provisional license to be renewed yearly & will be converted to fully standard license after meeting licensing commitments.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.